Summary
Steve Prestrelski is a veteran biopharmaceutical executive and founder with over 35 years of experience translating laboratory innovation into marketed medicines and drug-delivery systems. He has led R&D, product development, business development and portfolio strategy across startups and global pharma, playing instrumental roles in bringing products like Byetta®, Bydureon®, Symlin®, Gvoke® and others to market. A serial founder and CEO, Steve has raised over $500M across seed to public financings and built companies such as Xeris Pharmaceuticals and Athysis. He pairs a PhD in Biomedical Science with an MBA in New Venture Development and Finance, enabling a rare blend of deep scientific credibility and commercial acumen. Active on boards and advisory councils, he brings hands-on experience across metabolic disease, oncology and pain management plus expertise in advanced drug delivery systems. An underappreciated strength is his consistent ability to shepherd technologies from concept through complex regulatory and manufacturing pathways to scalable, patient-facing products.
8 years of coding experience
26 years of employment as a software developer
PhD Biomedical Science, PhD Biomedical Science at The City University of New York
BS Nutrition Science, BS Nutrition Science at Drexel University
MBA New Venture Development and Finance, MBA New Venture Development and Finance at University of California, San Diego - Rady School of Management